Thomas A. Ban’s reply to Donald F. Klein’s comment on his essay on Conflict of Interest in Neuropsychopharmacology: Marketing vs. Education

I appreciate and share your concern about lack of “open access” (transparency) of data generated in clinical (and all other) research with psychotropic drugs. Yet the lack of open access is primarily a legal issue, as the proprietary nature of that information is protected by the law. It should not distract attention from the inherent conflict between marketing and education and the need for psychiatric research to identify pharmacologically more homogeneous populations than the populations identified by current consensus-based diagnoses

Thomas A. Ban

February 5, 2015